Low Dose Epcoritamab Plus GemOx in R/R DLBCL

This study tests a combination of a lower-than-standard dose of a newer antibody drug called epcoritamab together with a chemotherapy regimen (gemcitabine + oxaliplatin) for patients with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to previous treatment. **You may be eligible if...** - You have been diagnosed with relapsed or refractory diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma) - You have received at least one prior treatment - You are a candidate for a stem cell transplant using your own cells - You are in good enough physical condition (ECOG score 0–2) - You are willing to use contraception if you are of reproductive age **You may NOT be eligible if...** - You have an active bacterial, viral, or fungal infection - You have already had a stem cell transplant (either your own or a donor's) - You have another active cancer - You have severe organ failure Talk to your doctor to see if this trial is right for you.